RYR1

Ryanodine receptor 1 · P21817 · RYR1 on Sugi Atlas →

85 patent compounds predicted against RYR1, 56 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Bastadin 20 (SCHEMBL6796056)	0.73	10/20
SCHEMBL6805004	0.73	10/20
Bastadin 7 (SCHEMBL4338482)	0.92	9/20
SCHEMBL20365680	0.55	8/20
SCHEMBL19200594	0.46	8/20
SCHEMBL29374025	0.36	4/20
SCHEMBL28864122	0.38	2/20
SCHEMBL22835748	0.35	2/20
SCHEMBL394896	0.34	2/20
Acerogenin C (SCHEMBL4112475)	0.34	2/20
Epiryanodine (SCHEMBL118946)	1.00	1/20
Epiryanodine (SCHEMBL159872)	1.00	1/20
Epiryanodine (SCHEMBL5933502)	1.00	1/20
Epiryanodine (SCHEMBL13479886)	1.00	1/20
Epiryanodine (SCHEMBL13912554)	1.00	1/20
Epiryanodine (SCHEMBL20100627)	1.00	1/20
Epiryanodine (SCHEMBL20104624)	1.00	1/20
Epiryanodine (SCHEMBL25722480)	1.00	1/20
Epiryanodine (SCHEMBL31236365)	1.00	1/20
Epiryanodine (SCHEMBL4318989)	0.98	1/20

Clinical trials — most relevant to RYR1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effects of Carvedilol on Suppressing the Premature Ventricular Complex/Ventricular Tachycardia From Outflow Tract	PHASE4	UNKNOWN
Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction (AMI) Patients According to CYP2C19 Polymorphism	PHASE4	COMPLETED
A Clinical Trial Utilizing Dantrolene in Patients With Ventricular Arrhythmias.	PHASE2/PHASE3	COMPLETED
Levosimendan in Acute Decompensated Heart Failure	PHASE2/PHASE3	NOT_YET_RECRUITING
Antioxidant Therapy in RYR1-Related Congenital Myopathy	PHASE1/PHASE2	COMPLETED
A Phase I/II, First-In-Human Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Activity to Prevent or Treat Neuropsychiatric Symptoms in Pediatric Subjects With Timothy Syndrome	PHASE1/PHASE2	NOT_YET_RECRUITING
Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease	PHASE2	COMPLETED
S 48168 (ARM 210) for the Treatment of RYR1-related Myopathies (RYR1-RM)	PHASE1	COMPLETED
Evaluation of A Clinical Diagnostic Test for CRDS	nan	RECRUITING
The Prevalence of RYR1-related Disease	nan	NOT_YET_RECRUITING
Multispectral Optoacoustic Tomography for Advanced Imaging of Centronuclear Myopathy	nan	RECRUITING
International CRDS Registry	nan	RECRUITING
A Natural History Study of RYR1-Related Disorders	nan	RECRUITING
Early Detection of Cardiomyopathy by Speckle Echo, High Sensitive Troponin and Cardiac Ryanodine Receptors	nan	UNKNOWN
Role of Amino Acids and Genetic Disorder in Pathogenesis of Heart Failure	nan	UNKNOWN
Malignant Hyperthermia in Czech Republic: Description of the Biggest Slavonic Group of Patients Investigated for Risk of Malignant Hyperthermia	nan	COMPLETED
Calcium Handling and Epicardial Ablation	nan	COMPLETED
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives	nan	UNKNOWN
Carnosine Supplementation on Quantity/Quality of Oral Salivae.	nan	UNKNOWN
Endomysial Fibrosis, Muscular Inflammatory Response and Calcium Homeostasis Dysfunction in Duchenne Muscular Dystrophy	nan	UNKNOWN
Contractile Cross Sectional Areas and Muscle Strength in Patients With Congenital Myopathies	nan	COMPLETED
Manganese-Enhanced Magnetic Resonance Imaging (MEMRI) in Ischaemic, Inflammatory and Takotsubo Cardiomyopathy (MEMORY)	nan	COMPLETED
Multisystem Features of Malignant Hyperthermia or Rhabdomyolysis Related to RYR1 Variants	nan	UNKNOWN
Uterine Cooling During Cesarean Delivery to Reduce Blood Loss and Incidence of Postpartum Hemorrhage	nan	COMPLETED
Evaluate the Effort Test as a Therapeutic Monitoring Tool in Acute Rhabdomyolyses	nan	COMPLETED
Spanish Registry of RYR1 and CACNA1S Polymorphisms	nan	UNKNOWN
Population at Risk of Malignant Hyperthermia: Ambispective Cohort.	nan	UNKNOWN
Heart and Skeletal Muscle Problems in Neuroacanthocytosis	nan	COMPLETED
A Novel Technique Of Uterine Cooling During Repeated Cesarean Section For Reducing Blood Loss	nan	COMPLETED
Tart Cherry Juice for Exercise Performance and Recovery	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a RYR1 binder may also engage these)

Protein	Name	Similarity
P11716	—	1.000	P11716 →
E9PZQ0	—	1.000	E9PZQ0 →
P16960	—	1.000	P16960 →
F1LMY4	—	1.000	F1LMY4 →
A2AGL3	—	0.998	A2AGL3 →
Q9TS33	—	0.997	Q9TS33 →
B0LPN4	—	0.997	B0LPN4 →
P30957	—	0.996	P30957 →
RYR2	Ryanodine receptor 2	0.996	landscape →
Q15413	—	0.993	Q15413 →
E9Q401	—	0.991	E9Q401 →
Q6NYU2	—	0.976	Q6NYU2 →
Q1LVW0	—	0.972	Q1LVW0 →
P48553	—	0.970	P48553 →
Q24498	—	0.969	Q24498 →
O94844	—	0.969	O94844 →
Q32LP0	—	0.968	Q32LP0 →
Q8N6S4	—	0.968	Q8N6S4 →
Q8TAP6	—	0.967	Q8TAP6 →
Q5RCP7	—	0.967	Q5RCP7 →
Q8K1B8	—	0.967	Q8K1B8 →
Q9BZ71	—	0.967	Q9BZ71 →
Q8IWV8	—	0.967	Q8IWV8 →
Q8QFR2	—	0.967	Q8QFR2 →
P29994	—	0.967	P29994 →
ITPR1	Inositol 1,4,5-trisphosphate-gated calcium channel ITPR1	0.966	landscape →
Q9NXN4	—	0.966	Q9NXN4 →
P11881	—	0.966	P11881 →
P0C7A6	—	0.966	P0C7A6 →
Q8BWW9	—	0.966	Q8BWW9 →